



# Update on coronavirus disease and retinal artery occlusion

Marianne L Shahsuvaryan <sup>1</sup>

<sup>1</sup> Department of Ophthalmology, Yerevan State Medical University, Yerevan, Armenia

## ABSTRACT

**Background:** The novel coronavirus disease 2019 (COVID-19) is significant not only for its life-threatening impact, but also for its association with serious eye disorders, including retinal artery occlusion. This language-inclusive narrative review analyzed the available clinical literature on retinal artery occlusion linked to COVID-19, highlighting it as a serious vision-threatening complication of this disease during the recent pandemic.

**Methods:** A targeted literature search was conducted in the PubMed / MEDLINE and Google Scholar databases from January 1, 2020, to January 1, 2025, to gather the most recent evidence. Studies were identified through various combinations of the following search terms: "eye diseases in COVID-19," "ocular findings," "ocular manifestations in COVID-19," "posterior segment alterations in COVID-19," and "retinal artery occlusion in COVID-19." Articles with relevant clinical significance were selected for review. The reference lists of these papers also manually checked for other relevant papers. We included case reports, case series, and both prospective and retrospective studies that reported cases of central retinal artery occlusion (CRAO) or branch retinal artery occlusion (BRAO) in patients of any age, sex, and race with confirmed COVID-19.

**Results:** We found 27 records, of which 21 reported cases of CRAO in patients with COVID-19. The mean (standard deviation) age of these patients was 54.1 (13.4) years (range: 30–77 years). Of the 21 patients, 18 (86%) were men and three (14%) were women. In three cases, bilateral involvement was noted; in one such instance, CRAO was diagnosed sequentially: in the left eye while the patient had COVID-19, and in the right eye 1.5 months later. Among the cases of unilateral CRAO, the left eye was the most frequently affected. Additionally, four cases of BRAO were reported in patients with COVID-19, with most of these patients being women. Most of these cases were diagnosed in the left eye within 1 month of a COVID-19 diagnosis. Notably, in the majority of cases involving CRAO or BRAO, vascular thromboembolic events were not reported. Additionally, two case series reported a total of 17 patients with COVID-19 who were diagnosed with CRAO.

**Conclusions:** Although strong evidence of a causal relationship is lacking, healthcare specialists should be aware that CRAO or BRAO may be ocular complications of COVID-19. This is particularly important with the emergence of new subvariants of SARS-CoV-2 and in asymptomatic patients, and considering the availability of rapid viral antigen tests will make it easier to check if the patient with CRAO or BRAO actually have asymptomatic COVID-19.

## KEYWORDS

SARS-CoV-2, COVID-19, ocular manifestations, branch retinal artery occlusion, central retinal artery occlusion

**Correspondences:** Marianne L. Shahsuvaryan, Department of Ophthalmology, Yerevan State Medical University, Yerevan, Armenia. Email: [mar\\_shah@hotmail.com](mailto:mar_shah@hotmail.com). ORCID iD: <https://orcid.org/0000-0003-3627-4137>

**How to cite this article:** Shahsuvaryan ML. Update on coronavirus disease and retinal artery occlusion. *Med Hypothesis Discov Innov Optom.* 2024 Winter; 5(4): 169-177. DOI: <https://doi.org/10.51329/mehdiptometry212>

Received: 02 January 2025; Accepted: 28 February 2025



Copyright © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.



## INTRODUCTION

Central retinal artery occlusion (CRAO) is a vaso-occlusive disorder of the retinal artery, representing a “retinal stroke.” It should be considered an ophthalmic emergency, as it can cause profound acute vision loss and even blindness [1]. Its mean standardized incidence rate is 2.00 cases per 100 000 person-years [2]. The first case of CRAO was reported by Van Graefe in 1859 [3]. The pathogenesis of CRAO has varied systemic and local implications. CRAO is most commonly caused by embolism or thrombosis caused by hemodynamic changes or large artery atherosclerosis [4].

On January 30th, 2020, the World Health Organization announced the outbreak of the extremely transmissible novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which represented “a public health emergency of international concern” [5]. Clinical medicine has witnessed an explosion in the number of ocular manifestations, ranging from 2% up to 60%, in patients with COVID-19 since the onset of the global pandemic [6-16]. Currently, available findings highlight a direct impact of SARS-CoV-2 on the surface of the eye, usually clinically seen as viral conjunctivitis [16-18], as well as an indirect impact on intraocular structures [16, 19, 20].

SARS-CoV-2 plays an important role in the pathophysiology of several conditions and can be life-threatening. However, it also plays a role in the pathophysiology of sight-threatening disorders of the eye [19, 20], such as retinal artery occlusion [17, 19, 20]. This is potentiated by prone positioning in the critical care setting [21]. In this language-inclusive narrative review, we aimed to analyze the clinical data available in the literature regarding retinal artery occlusion associated with COVID-19 as a serious sight-threatening complication during the recent pandemic.

## METHODS

A targeted literature search was conducted using the PubMed / MEDLINE and Google Scholar databases from January 1, 2020, to January 1, 2025, to retrieve the most recent evidence. Papers were identified by using various combinations of the following search terms: “eye diseases in COVID-19,” “ocular findings,” “ocular manifestations in COVID-19,” “posterior segment alterations in COVID-19,” and “retinal artery occlusion in COVID-19.”

Articles with acceptable clinical relevance were selected for review. The reference lists of these papers also manually checked for other relevant papers. We included case reports, case series, and any prospective or retrospective studies reporting central retinal artery occlusion (CRAO) or branch retinal artery occlusion (BRAO) in patients of any age, sex, and race with confirmed COVID-19.

## RESULTS

We identified 27 papers, including two cases series [22, 23] and 25 case reports, representing 21 patients with COVID-19 who had been diagnosed with CRAO [24-44] and four who had been diagnosed with BRAO [45-48]. Table 1 summarizes demographic and clinical characteristic of cases [24-44] with CRAO who had a mean (standard deviation) age of 54.1 (13.4) years (range: 30–77 years). Of the 21 patients with CRAO, 18 (86%) were men and three (14%) were women. Three had bilateral involvement [35, 36, 44]. In one of these patients, the bilateral CRAO was detected in a sequential order, where the left eye developed CRAO simultaneous with COVID-19, and CRAO was detected in the right eye 1.5 months later [36]. Among the patients with unilateral CRAO [24-34, 37-43], the left eye was the most frequently affected [25, 27, 29, 32, 34, 39, 41-43].

Acharya et al. [24] presented the first case of COVID-10-associated CRAO in a 60-year-old Hispanic male who was diagnosed with CRAO on the 12th day of hospitalization for COVID-19. The authors stated that this diagnosis has not been described in the natural history of COVID-19 up to that point, and was associated with poor visual outcomes. Multiple similar cases were subsequently presented by different researchers [25-34], some of which were associated with remarkable neuroradiological findings, such as internal carotid artery obstruction [30-32, 40, 49, 50].

Lecler et al. [50] reported nine consecutive patients with severe COVID-19 who exhibited abnormalities on globe magnetic resonance imaging. Among them, one was diagnosed with unilateral CRAO through fluorescein angiography. However, due to insufficient data about this patient, this case was not included. Murchison et al. [31] diagnosed CRAO as the initial manifestation of COVID-19 with a large thrombus extending into the internal carotid artery revealed by neuroimaging (Table 1). Another report described a fatal case, in which a 77-year-old male hospitalized with moderate COVID-19 developed severe disease with a devastating “thromboembolic storm,” which included right eye CRAO during the recovery stage of COVID-19, on the 16th day since symptoms started [33] (Table 1).

Another case of CRAO was documented in an otherwise healthy 63-year-old male who was admitted to the intensive care unit on the 21 days since recovery from COVID-19 [34] (Table 1). Bilateral cases of CRAO were also documented in different periods of COVID-19 [35, 36, 44] (Table 1).

Table 2 summarizes the demographic and clinical characteristic of the four reported cases of BRAO that were diagnosed in patients with COVID-19 [45-48]. Three of the four patients were women [45-47] and the left eye was affected in three cases [45, 46, 48], mostly within 1 month of a COVID-19 diagnosis [46-48].

Table 1. Characteristics of reported cases [24-44] of CRAO associated with COVID- 2019

Author (Year)	Age (y) /Sex / Race	Laterality	Time interval	Severity of COVID-19	Vascular thromboembolic events	Relevant note
Acharya et al. (2020) [24]	60 / M / Hispanic	RE	12 days	Severe	No	-
Montesel et al (2020) [25]	59 / M / African	LE	17 days	Severe	No	Acute renal injury requiring hemodialysis.
Turedi and Onal Gunay (2021) [26]	54 / M / Turkic	RE	14 days	Mild	No	-
Latigan et al. (2021) [27]	31/ W / Russian	LE	> 21 days	Moderate	No	Hypercoagulation.
Ucar and Centinkaya (2021) [28]	54 / M / Turkic	RE	21 days	Mild	No	-
Been Sayeed et al. (2021) [29]	38 / M / Bangali	LE	7 days	Severe (Fatal)	Acute ischemic stroke.	Diabetes mellitus.
Sweid et al. (2020) [30]	59 / M / NA	Unilateral	Simultaneous	Mild	Internal carotid artery occlusion.	Hypertension.
Murchison et al. (2021) [31]	50 / M / NA	RE	Asymptomatic	NA	Internal carotid artery occlusion.	Hypertension.
Paul et al. (2022) [32]	30 / M / Indian	LE	3 months	Mild	Ophthalmic artery occlusion, posterior ciliary artery occlusion, and proven internal carotid artery occlusion.	Ischemic stroke with right hemiparesis, global aphasia, and right upper motor neuron facial palsy. Cilioretinal artery occlusion.
Jervis et al. (2022) [33]	77 / M / NA	RE	16 days	Moderate turned into severe(Fatal)	Spleen, kidneys, and peripheral vasculature "thromboembolic storm."	Rheumatoid arthritis, diabetes mellitus, and hypertension.
Shroff et al. (2022) [34]	63 / M / Indian	LE	21 days	Severe	No	-
Bapaye et al. (2021) [35]	42 / M / Indian	Bilateral	1-month	Moderate	No	-
Karahan et al. (2021) [36]	61 / M / Turkic	Bilateral	Left eye with simultaneous involvement, but RE with 1.5 months interval.	Moderate	No	Asthma.
Walinjkar (2021) [37]	66 / M / Indian	RE	-	Asymptomatic	No	Simultaneous central retinal vein occlusion.
Sanjay et al. (2021) [38]	66 / M / Indian	RE	4 days	Mild	No	Bilateral panuveitis.
Raj et al. (2021) [39]	37 / M / Indian	LE	14 days	Severe	No	Cavernous sinus thrombosis.
Larochelle et al. (2022) [40]	68 / M / Caucasian	RE	3 days	Severe	Acute kidney injury, atrial fibrillation.	Internal carotid artery occlusion and sixth cranial nerve palsy.
Yalcinbayir et al. (2023) [41]	66 / M / Turkic	LE	14 days	Mild	No	-
Heidarzadeh et al. (2023) [42]	44 / M / Persian	LE	21 days	Severe	No	Pneumonia and uveitis.
de Oliveria et al. (2023) [43]	68 / W / Brazilian	LE	23 days	Severe	Elevated fibrinogen.	Hypertension.
Blyden et al. (2024) [44]	44 / W / NA	Bilateral	19 days	Severe	Elevated platelet.	Type 2 diabetes mellitus.

Note: CRAO, central retinal artery occlusion; COVID-19, coronavirus disease 2019; y, year-old; M, man; W; woman; NA, not available; Time interval, the time interval between COVID-19 infection and the onset of CRAO; LE, left eye; RE, right eye.

**Table 2. Characteristics of reported cases [45-48] of BRAO associated with COVID- 2019**

Author (Year)	Age (y) / Sex / Race	Laterality	Time interval	COVID-19 Severity	Vascular thromboembolic events	Relevant note
Uzun et al. (2021) [45]	65 / W / Turkic	LE	5 weeks	Mild	No	-
Nourinia et al. (2021) [46]	60 / W / Persian	LE	10 days	Severe	No	Meningoencephalitis
Ates et al. (2021) [47]	34 / W / Turkic	RE	25 days	Mild	No	-
Jiang et al. (2024) [48]	79 / M / Chinese	LE	2 weeks	Mild	No	Hypertension

Note: BRAO, branch retinal artery occlusion; COVID-19, coronavirus disease 2019; Y, year-old; M, man; W, woman; Time interval, the time interval between COVID-19 infection and the onset of branch retinal artery occlusion; LE, left eye; RE, right eye.

The two case series described 17 patients with COVID-19 who had been diagnosed with CRAO [22, 23]. A retrospective study evaluating the frequency of SARS-CoV-2 among 15 patients (7 males and 8 females) with CRAO, who attended a tertiary referral hospital between March and November 2020, demonstrated no infection by SARS-CoV-2 before episodes of CRAO. However, the authors stated that their results required further comprehensive assessment taking into account confounding factors [22]. Likely explanations for this lack of correlation are that COVID-19 rarely manifests solely with CRAO, or that the majority of CRAO cases were diagnosed in patients with severe COVID-19 [24, 25, 29, 34, 39, 40, 42-44] who were hospitalized in non-ophthalmic medical centers, including intensive care units. A multicenter retrospective study of COVID-19-related retinal vascular occlusions, diagnosed during March 2020 and September 2021 [23], documented two cases with CRAO among 15 eligible cases. The authors concluded that occlusion could manifest simultaneously with COVID-19 or weeks later, typically affecting patients younger than 60 years [23].

## DISCUSSION

Current clinical evidence suggests a potential link between COVID-19 and CRAO or BRAO. Reports indicate that patients with COVID-19 may develop CRAO or BRAO, regardless of the severity of their COVID-19 symptoms, as cases ranged from asymptomatic individuals to those with critical illness [22, 23, 24-44, 45-48].

The pathogenesis of CRAO has varied systemic and local implications. CRAO is most commonly caused by embolism or thrombosis associated with hemodynamic changes or atherosclerosis [4]. CRAO is hypothesized to result from thromboembolism in addition to inflammation and hypercoagulation secondary to SARS-CoV-2 infection [51-59]. Increasing evidence indicates that this virus could also cause vaso-occlusion of the retinal artery [16, 22-50] due to its thromboembolic effects [49]. The proposed mechanism of destructive impact is as follows: the virus reaches the intraocular structures through the bloodstream [60], targeting tissues expressing angiotensin-converting enzyme 2 [61], including the retinal vascular network and retinal pigment epithelium [62, 63]. After binding to this receptor, it then triggers a cascade of inflammatory events, which is followed by endothelial dysfunction [51, 52], platelet activation, and hypercoagulability [53], leading to thrombotic complications [64]. A number of recent studies have shown different vascular and retinal abnormalities with clinical and subclinical manifestations detected in cases of mild and severe COVID-19 [65-75], which have also been confirmed by a postmortem study [76, 77].

Recently Abbati et al. [78] described the first case of a 6-year-old otherwise healthy girl who was diagnosed with CRAO after a 1-day fever. The authors stated that this has not been reported in the natural history of COVID-19 in the pediatric population and was associated with poor visual outcomes [78]. These findings suggest that SARS-CoV-2 could potentially cause CRAO in any age group. While the mean age of patients with CRAO and COVID-19 described in included case reports was 54.1 years [24-44], almost all cases were  $\geq 30$  years. A recent study funded by the National Institutes of Health [77] provided new evidence of the direct impact of SARS-CoV-2 infection on the arteries of the heart, which increase the risk of heart attack and stroke [77]. With this in mind, it should be considered that CRAO and the resulting retinal ischemia [49] represents a "retinal stroke."

COVID-19 remains a significant and evolving issue. It is important to stay informed about the disease and be aware of any emerging symptoms. [79]. This is particularly important given the possibility of reinfection and the current circulation of various subtypes of SARS-CoV-2 such as the emerging subvariant BA.2.86, also known as "Pirola." This subvariant has a significant number of mutations that may enhance its ability to evade the immune system [80]. Reinfection may result in more chronic, multi-organ complications, which could have serious implications for ocular health [81].

Recent reviews, such as those by Stawowski et al. [79], Ng et al. [81], Eissa et al. [82], Patel et al. [83], Parmar et al. [84], and Salvetat and Zeppieri [85], have covered a significant number of studies that have evaluated the ocular manifestations of COVID-19. The general consensus is that CRAO could occur in patients with COVID-19. Further supportive data for this notion were reported by Micevych and Stewart [86]. However, the evidence regarding COVID-19-associated CRAO remains inconclusive due to the limited number of reported cases [49]. This highlights the need for big data [87, 88] and multicenter cohort studies to verify causal relationships.

This review summarized the demographic and clinical characteristics of patients who developed CRAO or BRAO in connection with COVID-19, as reported in the scientific literature over the past 5 years. However, the absence of a systematic review search strategy may have led to the oversight of some important studies on this topic. Furthermore, the existing evidence was primarily derived from case reports and case series, making it difficult to draw definitive conclusions about the causal relationship of COVID-19 with CRAO or BRAO. Consequently, further research, including systematic reviews and meta-analyses, is necessary to establish clearer conclusions. Additionally, multicenter cohort studies are needed to verify causal relationships between COVID-19 disease and retinal vascular occlusive diseases.

## CONCLUSIONS

Despite the lack of strong evidence confirming a causal relationship, healthcare specialists should remain vigilant regarding cases of CRAO or BRAO as potential ocular complications associated with COVID-19. This is particularly important with the emergence of new subvariants of SARS-CoV-2 and in asymptomatic patients. With using available rapid antigen tests for SARS-CoV-2, establishing whether CRAO or BRAO are complications of infection with this virus will be facilitated. Early identification and prompt management of patients with COVID-19 exhibiting ocular manifestations—particularly those that threaten vision—can reduce ocular complications, mitigate the severity of the viral disease, facilitate quicker recovery, and help prevent the spread of infection within both the medical and general communities.

## ETHICAL DECLARATIONS

**Ethical approval:** No ethical approval was required.

**Conflict of interests:** None.

## FUNDING

None.

## ACKNOWLEDGMENTS

None.

## REFERENCES

1. Altabás MJ, Arias-Peso B, Altabás MA. Abrupt loss of vision: Retinal artery occlusion. *Visual Journal of Emergency Medicine*. 2022 Jan 1;26:101266. doi: [10.1016/j.visj.2021.101266](https://doi.org/10.1016/j.visj.2021.101266)
2. Kim J, Byun SJ, Woo SJ, Park KH, Park SJ. Assessment of Trends in the Incidence Rates of Central Retinal Artery Occlusion in Korea From 2002 to 2015. *JAMA Ophthalmol*. 2021 Apr 1;139(4):399-405. doi: [10.1001/jamaophthalmol.2020.6860](https://doi.org/10.1001/jamaophthalmol.2020.6860). PMID: 33570556; PMCID: [PMC7879389](https://pubmed.ncbi.nlm.nih.gov/PMC7879389/).
3. Venkatesh R, Joshi A, Maltsev D, Munk M, Prabhu V, Bavaskar S, Mangla R, Ruamviboonsuk P, Chhablani J. Update on central retinal artery occlusion. *Indian J Ophthalmol*. 2024 Jul 1;72(7):945-955. doi: [10.4103/IJO.IJO\\_2826\\_23](https://doi.org/10.4103/IJO.IJO_2826_23). Epub 2024 Jun 22. PMID: 38905460; PMCID: [PMC11329807](https://pubmed.ncbi.nlm.nih.gov/PMC11329807/).
4. Schorr EM, Rossi KC, Stein LK, Park BL, Tuhim S, Dharamoon MS. Characteristics and Outcomes of Retinal Artery Occlusion: Nationally Representative Data. *Stroke*. 2020 Mar;51(3):800-807. doi: [10.1161/STROKEAHA.119.027034](https://doi.org/10.1161/STROKEAHA.119.027034). Epub 2020 Jan 17. PMID: 31951154.
5. Yusefi AR, Sharifi M, Nasabi NS, Rezabeigi Davarani E, Bastani P. Health human resources challenges during COVID-19 pandemic; evidence of a qualitative study in a developing country. *PLoS One*. 2022 Jan 24;17(1):e0262887. doi: [10.1371/journal.pone.0262887](https://doi.org/10.1371/journal.pone.0262887). PMID: 35073374; PMCID: [PMC8786119](https://pubmed.ncbi.nlm.nih.gov/PMC8786119/).
6. Reviglio VE, Osaba M, Reviglio V, Chiaradia P, Kuo IC, O'Brien TP. COVID-19 and Ophthalmology: A New Chapter in an Old Story. *Med Hypothesis Discov Innov Ophthalmol*. 2020 Summer;9(2):71-73. Epub 2020 Mar 4. PMID: 32490013; PMCID: [PMC7134243](https://pubmed.ncbi.nlm.nih.gov/PMC7134243/).
7. Hu K, Patel J, Swiston C, Patel BC. Ophthalmic Manifestations of Coronavirus (COVID-19). 2024 May 6. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 32310553.
8. Jevnikar K, Jaki Mekjavic P, Vidovic Valentincic N, Petrovski G, Globocnik Petrovic M. An Update on COVID-19 Related Ophthalmic Manifestations. *Ocul Immunol Inflamm*. 2021 May 19;29(4):684-689. doi: [10.1080/09273948.2021.1896008](https://doi.org/10.1080/09273948.2021.1896008). Epub 2021 Apr 7. PMID: 33826465.
9. Bertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, Gambato T, Lanzetta P. Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. *J Ophthalmol*. 2020 Aug 27;2020:4827304. doi: [10.1155/2020/4827304](https://doi.org/10.1155/2020/4827304). PMID: 32963819; PMCID: [PMC7491448](https://pubmed.ncbi.nlm.nih.gov/PMC7491448/).
10. Szczęśniak M, Brydak-Godowska J. SARS-CoV-2 and the Eyes: A Review of the Literature on Transmission, Detection, and Ocular Manifestations. *Med Sci Monit*. 2021 Sep 11;27:e931863. doi: [10.12659/MSM.931863](https://doi.org/10.12659/MSM.931863). PMID: 34508064; PMCID: [PMC8439119](https://pubmed.ncbi.nlm.nih.gov/PMC8439119/).
11. Keyal K, Wang F. Ophthalmic Manifestations in COVID-19 Patients, a Review. *Discov Med*. 2021 Jul-Aug;32(165):7-11. PMID: 35219351.
12. Roshanshad A, Ashraf MA, Roshanshad R, Kharmandar A, Zomorodian SA, Ashraf H. Ocular Manifestations of Patients with Coronavirus Disease 2019: A Comprehensive Review. *J Ophthalmic Vis Res*. 2021 Apr 29;16(2):234-247. doi: [10.18502/jovr.v16i2.9087](https://doi.org/10.18502/jovr.v16i2.9087). PMID: 34055261; PMCID: [PMC8126735](https://pubmed.ncbi.nlm.nih.gov/PMC8126735/).
13. Douglas KAA, Douglas VP, Moschos MM. Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature. *In Vivo*. 2020 Jun;34(3 Suppl):1619-1628. doi: [10.21873/invivo.11952](https://doi.org/10.21873/invivo.11952). PMID: 32503820; PMCID: [PMC8378034](https://pubmed.ncbi.nlm.nih.gov/PMC8378034/).



14. Bal S, Chodosh J. Ocular Manifestations, Virulence, and Transmissibility of SARS-CoV-2: A Review of the Literature by Region. *Int Ophthalmol Clin*. 2022 Apr 1;62(2):1-18. doi: 10.1097/IIO.0000000000000420. PMID: 35325907.
15. Chougule N, Mangoli MV, Kumar A, Reddy VB, Tenagi AL. Ocular manifestations in SARS COVID admitted patients: A hospital-based study. *Indian Journal of Health Sciences and Biomedical Research kleu*. 2022 Jan 1;15(1):46-9. doi: 10.4103/kleuhj.kleuhj\_168\_21.
16. Tran E, Phu V, Xu R, Teoderascu A, Aly M, Shah N, Malvankar-Mehta MS. Ocular manifestations of COVID-19: systematic review and meta-analysis. *Can J Ophthalmol*. 2024 Oct;59(5):e435-e452. doi: 10.1016/j.cjco.2023.08.003. Epub 2023 Sep 5. PMID: 37683691.
17. Rokohl AC, Grajewski RS, Matos PAW, Kopecky A, Heindl LM, Cursiefen C. Ocular Involvement in COVID-19: Conjunctivitis and More. *Klin Monbl Augenheilkd*. 2021 May;238(5):555-560. English, German. doi: 10.1055/a-1344-8138. Epub 2021 May 21. PMID: 34020483.
18. Madani S. Acute and sub-acute ocular manifestations in pediatric patients with COVID-19: A systematic review. *Med Hypothesis Discov Innov Ophthalmol*. 2022 Apr 1;11(1):11-18. doi: 10.51329/mehdiophthal1440. PMID: 37641695; PMCID: PMC10445324.
19. D'Alessandro E, Kawasaki A, Eandi CM. Pathogenesis of Vascular Retinal Manifestations in COVID-19 Patients: A Review. *Biomedicines*. 2022 Oct 26;10(11):2710. doi: 10.3390/biomedicines10112710. PMID: 36359227; PMCID: PMC9687698.
20. Invernizzi A. The impact of COVID-19 on the retina: clinical features and management considerations. *Expert Review of Ophthalmology*. 2022 Jan 2;17(1):53-60. doi:10.1080/17469899.2022.2021877.
21. Sanghi P, Malik M, Hossain IT, Manzouri B. Ocular Complications in the Prone Position in the Critical Care Setting: The COVID-19 Pandemic. *J Intensive Care Med*. 2021 Mar;36(3):361-372. doi: 10.1177/0885066620959031. Epub 2020 Sep 28. PMID: 32985317.
22. Au SC, Ko CK. Prevalence of SARS-CoV-2 among central retinal artery occlusion patients: A case series-HORA study report No. 3. *Journal of Acute Disease*. 2021 Jul 1;10(4):147-9. doi: 10.4103/2221-6189.318644.
23. Fonollosa A, Hernández-Rodríguez J, Cuadros C, Giralt L, Sacristán C, Artaraz J, Pelegrín L, Olate-Pérez Á, Romero R, Pastor-Idoate S, Sobas Bsc EM, Fernández-Fidalgo S, Abraldes MJ, Oleñik A, Insausti-García A, Torres P, Porcar C, Lorca DR, Adan A; Spanish Society of Ocular Inflammation (SEIOC); Spanish Society of Ocular Inflammation (SEIOC). CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS: A Case Series and Review of the Literature. *Retina*. 2022 Mar 1;42(3):465-475. doi: 10.1097/IAE.0000000000003327. PMID: 34914345.
24. Acharya S, Diamond M, Anwar S, Glaser A, Tyagi P. Unique case of central retinal artery occlusion secondary to COVID-19 disease. *IDCases*. 2020;21:e00867. doi: 10.1016/j.idcr.2020.e00867. Epub 2020 Jun 18. PMID: 32572363; PMCID: PMC7301806.
25. Montesel A, Bucolo C, Mouvet V, Moret E, Eandi CM. Case Report: Central Retinal Artery Occlusion in a COVID-19 Patient. *Front Pharmacol*. 2020 Dec 23;11:588384. doi: 10.3389/fphar.2020.588384. PMID: 33424598; PMCID: PMC7785811.
26. Turedi N, Onal Gunay B. Paracentral acute middle maculopathy in the setting of central retinal artery occlusion following COVID-19 diagnosis. *Eur J Ophthalmol*. 2022 May;32(3):NP62-NP66. doi: 10.1177/1120672121995347. Epub 2021 Feb 14. PMID: 33583231; PMCID: PMC9111906.
27. Latigan KL, Latigan DA, Dubnov KE, Bykova EV, Nefedov DA. A clinical case of central retinal artery occlusion after pneumonia caused by SARS-COV-2 (COVID-19). *Acta Biomed Sci*. 2021;6:41-7. doi: 10.29413/ABS.2021-6.6-1.5.
28. Ucar F, Cetinkaya S. Central retinal artery occlusion in a patient who contracted COVID-19 and review of similar cases. *BMJ Case Rep*. 2021 Jul 27;14(7):e244181. doi: 10.1136/bcr-2021-244181. PMID: 34315751; PMCID: PMC8317104.
29. Been Sayeed SKJ, Chandra Das S, Mahmud R, Moniruzzaman M, Rahman MM. Acute Ischemic Stroke With Central Retinal Artery Occlusion as a Rare Presentation of COVID-19 Disease. *Cureus*. 2021 Aug 26;13(8):e17469. doi: 10.7759/cureus.17469. PMID: 34589363; PMCID: PMC8464349.
30. Sweid A, Hammoud B, Weinberg JH, Oneissi M, Raz E, Shapiro M, DePrince M, Tjoumakaris S, Gooch MR, Herial NA, Zarzour H, Romo V, Rosenwasser RH, Jabbour P. Letter: Thrombotic Neurovascular Disease in COVID-19 Patients. *Neurosurgery*. 2020 Sep 1;87(3):E400-E406. doi: 10.1093/neuros/nyaa254. PMID: 32496534; PMCID: PMC7313768.
31. Murchison AP, Sweid A, Dharia R, Theofanis TN, Tjoumakaris SI, Jabbour PM, Bilyk JR. Monocular visual loss as the presenting symptom of COVID-19 infection. *Clin Neurol Neurosurg*. 2021 Feb;201:106440. doi: 10.1016/j.clineuro.2020.106440. Epub 2020 Dec 15. PMID: 33383464; PMCID: PMC7831816.
32. Paul L, Jain T, Singh S. Retinal manifestations of ophthalmic artery occlusion with ischemic stroke in a young patient with COVID-19. *Indian J Ophthalmol*. 2022 Apr;70(4):1415-1417. doi: 10.4103/ijoo.IJO\_2828\_21. PMID: 35326070; PMCID: PMC9240522.
33. Jervis M, Purohit K, Greener V, Kumar R. Thromboembolic Storm in the Recovering Stage of COVID-19: A Case Report. *EMJ*. 2022 Mar;7(1):22-7. doi: 10.33590/emj/21-00210.
34. Shroff D, Kumar S, Naidu A, Gupta C, Shroff CM. Retinal vasooclusive spectrum following COVID-19. *Indian J Ophthalmol*. 2022 Apr;70(4):1412-1415. doi: 10.4103/ijoo.IJO\_2837\_21. PMID: 35326069; PMCID: PMC9240570.
35. Bapaye MM, Nair AG, Bapaye CM, Bapaye MM, Shukla JJ. Simultaneous Bilateral Central Retinal Artery Occlusion following COVID-19 Infection. *Ocul Immunol Inflamm*. 2021 May 19;29(4):671-674. doi: 10.1080/09273948.2021.1891262. Epub 2021 Apr 15. PMID: 33856275.
36. Karahan M, Erdem S, Hazar L, Dursun ME, Ava S, Emek H, Keklikci U. Bilateral Central Retinal Artery Occlusion Secondary to SARS-CoV-2 Infection in the Early and Late Periods: A Case Report. *Klin Monbl Augenheilkd*. 2021 Dec;238(12):1325-1327. English. doi: 10.1055/a-1353-5915. Epub 2021 Feb 19. PMID: 33607682.
37. Walinjar JA. Combined Retinal Vascular Occlusion in a Recovered Case of COVID-19. *Apollo Medicine*. 2021 Jul 1;18(3):205-7. doi: 10.4103/am.am\_38\_21.
38. Sanjay S, Srinivasan P, Jayadev C, Mahendradas P, Gupta A, Kawali A, Shetty R. Post COVID-19 Ophthalmic Manifestations in an Asian Indian Male. *Ocul Immunol Inflamm*. 2021 May 19;29(4):656-661. doi: 10.1080/09273948.2020.1870147. Epub 2021 Mar 18. PMID: 33733987.

39. Raj A, Kaur N, Kaur N. Cavernous sinus thrombosis with central retinal artery occlusion in COVID-19: A case report and review of literature. *Indian J Ophthalmol*. 2021 May;69(5):1327-1329. doi: 10.4103/ijo.IJO\_3770\_20. PMID: 33913893; PMCID: PMC8186592.
40. Laroche RD, Koduri VA, Chen RC, Subramanian PS. Embolic Abducens Palsy and Central Retinal Artery Occlusion in a Patient With COVID-19. *J Neuroophthalmol*. 2022 Jun 1;42(2):e500-e501. doi: 10.1097/WNO.0000000000001291. PMID: 33813532.
41. Yalçınbayır Ö, Uçan Gündüz G, Coşkun F, Hakyemez B, Doğanay S. Different Cases, Different Manifestations of Post-COVID-19 Retinal Artery Occlusion: A Case Series. *Turk J Ophthalmol*. 2023 Apr 20;53(2):124-129. doi: 10.4274/tjo.galenos.2022.36930. PMID: 37089035; PMCID: PMC10127544.
42. Heidarzadeh HR, Abrishami M, Motamed Shariati M, Ghavami Shahri SH, Ansari Astaneh MR. Atypical Central Retinal Artery Occlusion following COVID-19 Infection: A Case Report. *Case Rep Ophthalmol*. 2023 Aug 30;14(1):405-410. doi: 10.1159/000532108. PMID: 37901628; PMCID: PMC10601811.
43. de Oliveira MR, Lucena ARV, Higino TM, Ventura CV. Central retinal artery occlusion with cilioretinal artery sparing secondary to COVID-19: Additional ocular complication. *Indian J Ophthalmol*. 2023 Feb;71(2):663-666. doi: 10.4103/ijo.IJO\_1246\_22. PMID: 36727384; PMCID: PMC10228942.
44. Blyden KM, Fashina T, Randleman C, Pearce W, Wells J, Yeh S, Shantha JG. Ocular Ischemic Events and Vision Loss Associated with COVID-19 Acute Hypoxic Respiratory Failure. *COVID*. 2024 Jun 27;4(7):890-5. doi: 10.3390/covid4070061.
45. Uzun A, Keles Sahin A, Bektas O. A Unique Case of Branch Retinal Artery Occlusion Associated with a Relatively Mild Coronavirus Disease 2019. *Ocul Immunol Inflamm*. 2021 May 19;29(4):715-718. doi: 10.1080/09273948.2021.1933071. Epub 2021 Jul 12. PMID: 34252339.
46. Nourinia R, Ghassempour M, Ahmadi H, Abtahi SH. Branch retinal vein occlusion after COVID-19. *J Fr Ophtalmol*. 2021 Oct;44(8):e441-e443. doi: 10.1016/j.jfo.2021.06.003. Epub 2021 Jul 8. PMID: 34325925; PMCID: PMC8264517.
47. Ateş O, Yıldırım M, Yıldırım K. Branch Retinal Artery Occlusion in Patient with COVID-19: Case Report. *Korean J Ophthalmol*. 2021 Dec;35(6):484-485. doi: 10.3341/kjo.2021.0008. Epub 2021 Sep 6. PMID: 34488254; PMCID: PMC8666251.
48. Jiang Z, Ji H, Zhang H, Dong Z, Dong J. Branch retinal artery occlusion in a patient with COVID-19 infection: A case report. *J Int Med Res*. 2024 Oct;52(10):3000605241284931. doi: 10.1177/03000605241284931. PMID: 39351991; PMCID: PMC11529667.
49. Au SCL, Ko CKL. Central Retinal Artery Occlusion in Patients with COVID-19: Imaging for Underlying Causes. *Radiology*. 2021 Jul;300(1):E315. doi: 10.1148/radiol.2021210479. Epub 2021 Mar 30. PMID: 33787341; PMCID: PMC8893177.
50. Lecler A, Cotton F, Lersy F, Kremer S, Héran F; SFNR's COVID Study Group. Ocular MRI Findings in Patients with Severe COVID-19: A Retrospective Multicenter Observational Study. *Radiology*. 2021 May;299(2):E226-E229. doi: 10.1148/radiol.2021204394. Epub 2021 Feb 16. Erratum in: *Radiology*. 2022 Jan;302(1):E4. doi: 10.1148/radiol.2021219025. PMID: 33591889; PMCID: PMC7887777.
51. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020060000. PMID: 32339221; PMCID: PMC7273827.
52. Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily. *Br J Haematol*. 2020 Jun;189(6):e227-e230. doi: 10.1111/bjh.16783. Epub 2020 May 23. PMID: 32369610.
53. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol*. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11. PMID: 32407672; PMCID: PMC7213964.
54. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastiris E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziakas G, Dimopoulos MA. Hematological findings and complications of COVID-19. *Am J Hematol*. 2020 Jul;95(7):834-847. doi: 10.1002/ajh.25829. Epub 2020 May 23. PMID: 32282949; PMCID: PMC7262337.
55. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. *Inflamm Res*. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12. PMID: 32918567; PMCID: PMC7486586.
56. Mancuso P, Gidaro A, Gregato G, Raveane A, Cremonesi P, Quarna J, Caccia S, Gusso L, Rusconi S, Giacomelli A, Cogliati C, Bertolini F. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. *J Thromb Haemost*. 2020 Oct;18(10):2744-2750. doi: 10.1111/jth.15044. Epub 2020 Aug 31. PMID: 32762140; PMCID: PMC7436444.
57. Quinaglia T, Shabani M, Breder I, Silber HA, Lima JAC, Sposito AC. Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. *Atherosclerosis*. 2021 Apr;322:39-50. doi: 10.1016/j.atherosclerosis.2021.02.009. Epub 2021 Feb 15. PMID: 33706082; PMCID: PMC7883684.
58. Pérez-Mies B, Gómez-Rojo M, Carretero-Barrio I, Bardi T, Benito A, García-Cosío M, Caballero Á, de Pablo R, Galán JC, Pestaña D, Palacios J. Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. *Thorax*. 2021 Oct;76(10):1044-1046. doi: 10.1136/thoraxjnl-2020-216714. Epub 2021 Mar 23. PMID: 33758071; PMCID: PMC7992389.
59. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Agheno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fared J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McIntock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Constantinides SV, Weitz JJ, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID: 32311448; PMCID: PMC7164881.
60. Romero-Castro RM, Ruiz-Cruz M, Alvarado-de la Barrera C, González-Cannata MG, Luna-Villalobos YA, García-Morales AK, Ablanedo-Terrazas Y, González-Navarro M, Ávila-Ríos S. POSTERIOR SEGMENT OCULAR FINDINGS IN CRITICALLY ILL PATIENTS WITH COVID-19. *Retina*. 2022 Apr 1;42(4):628-633. doi: 10.1097/IAE.0000000000003457. PMID: 35350045.
61. Lukiw WJ. David Hunter Hubel, the 'Circe effect', and SARS-CoV-2 infection of the human visual system. *Front Biosci (Landmark Ed)*. 2022 Jan 6;27(1):7. doi: 10.31083/j.fb12701007. PMID: 35090312.

62. Casagrande M, Fitzek A, Püschel K, Aleshcheva G, Schultheiss HP, Berneking L, Spitzer MS, Schultheiss M. Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients. *Ocul Immunol Inflamm.* 2020 Jul 3;28(5):721-725. doi: [10.1080/09273948.2020.1770301](https://doi.org/10.1080/09273948.2020.1770301). Epub 2020 May 29. PMID: [32469258](https://pubmed.ncbi.nlm.nih.gov/32469258/).
63. Riotto E, Mégevand V, Mégevand A, Marti C, Pugin J, Stangos AN, Marconi Archinto L, Sunaric Mégevand G. Retinal Manifestations in Patients with COVID-19: A Prospective Cohort Study. *J Clin Med.* 2022 Mar 25;11(7):1828. doi: [10.3390/jcm11071828](https://doi.org/10.3390/jcm11071828). PMID: [35407441](https://pubmed.ncbi.nlm.nih.gov/35407441/); PMCID: [PMC8999406](https://pubmed.ncbi.nlm.nih.gov/PMC8999406/).
64. Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of COVID-19. *Am J Emerg Med.* 2021 Jan;39:213-218. doi: [10.1016/j.ajem.2020.09.065](https://doi.org/10.1016/j.ajem.2020.09.065). Epub 2020 Oct 1. PMID: [33036855](https://pubmed.ncbi.nlm.nih.gov/33036855/); PMCID: [PMC7528743](https://pubmed.ncbi.nlm.nih.gov/PMC7528743/).
65. Abrishami M, Emamverdian Z, Shoebi N, Omidtabrizi A, Daneshvar R, Saeidi Rezvani T, Saeedian N, Eslami S, Mazloumi M, Sadda S, Sarraf D. Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study. *Can J Ophthalmol.* 2021 Feb;56(1):24-30. doi: [10.1016/j.jco.2020.11.006](https://doi.org/10.1016/j.jco.2020.11.006). Epub 2020 Nov 14. PMID: [33249111](https://pubmed.ncbi.nlm.nih.gov/33249111/); PMCID: [PMC7666612](https://pubmed.ncbi.nlm.nih.gov/PMC7666612/).
66. Turker IC, Dogan CU, Dirim AB, Guven D, Kutucu OK. Evaluation of early and late COVID-19-induced vascular changes with OCTA. *Can J Ophthalmol.* 2022 Aug;57(4):236-241. doi: [10.1016/j.jco.2021.05.001](https://doi.org/10.1016/j.jco.2021.05.001). Epub 2021 May 21. PMID: [34118187](https://pubmed.ncbi.nlm.nih.gov/34118187/); PMCID: [PMC8139253](https://pubmed.ncbi.nlm.nih.gov/PMC8139253/).
67. Naderi Beni A, Dehghani A, Kianersi F, Ghanbari H, Habibidastanae Z, Memarzadeh SE, Naderi Beni Z. Retinal findings of COVID-19 patients using ocular coherence tomography angiography two to three months after infection: Ocular appearance recovered COVID-19 patient. *Photodiagnosis Photodyn Ther.* 2022 Jun;38:102726. doi: [10.1016/j.pdpdt.2022.102726](https://doi.org/10.1016/j.pdpdt.2022.102726). Epub 2022 Jan 17. PMID: [35051664](https://pubmed.ncbi.nlm.nih.gov/35051664/); PMCID: [PMC8762816](https://pubmed.ncbi.nlm.nih.gov/PMC8762816/).
68. Abrishami M, Hassanpour K, Hosseini S, Emamverdian Z, Ansari-Astaneh MR, Zamani G, Gharib B, Abrishami M. Macular vessel density reduction in patients recovered from COVID-19: a longitudinal optical coherence tomography angiography study. *Graefes Arch Clin Exp Ophthalmol.* 2022 Mar;260(3):771-779. doi: [10.1007/s00417-021-05429-0](https://doi.org/10.1007/s00417-021-05429-0). Epub 2021 Oct 12. PMID: [34636996](https://pubmed.ncbi.nlm.nih.gov/34636996/); PMCID: [PMC8505785](https://pubmed.ncbi.nlm.nih.gov/PMC8505785/).
69. Bayram N, Gundogan M, Ozsaygılı C, Adelman RA. Posterior ocular structural and vascular alterations in severe COVID-19 patients. *Graefes Arch Clin Exp Ophthalmol.* 2022 Mar;260(3):993-1004. doi: [10.1007/s00417-021-05420-9](https://doi.org/10.1007/s00417-021-05420-9). Epub 2021 Oct 4. PMID: [34605953](https://pubmed.ncbi.nlm.nih.gov/34605953/); PMCID: [PMC8488325](https://pubmed.ncbi.nlm.nih.gov/PMC8488325/).
70. Gündoğan M, Vural E, Bayram N, Altunel O, Gündoğan F, Göktaş S. Change in retinal vessel diameter and choroidal thickness in patients with severe COVID-19: Change In Retinal Parameters In Patients With Severe COVID-19. *Photodiagnosis Photodyn Ther.* 2022 Mar;37:102674. doi: [10.1016/j.pdpdt.2021.102674](https://doi.org/10.1016/j.pdpdt.2021.102674). Epub 2021 Dec 5. PMID: [34879296](https://pubmed.ncbi.nlm.nih.gov/34879296/); PMCID: [PMC8645280](https://pubmed.ncbi.nlm.nih.gov/PMC8645280/).
71. Banderas García S, Aragón D, Azarfane B, Trejo F, Garrell-Salat X, Sánchez-Montalvá A, Otero-Romero S, Garcia-Arumi J, Zapata MA. Persistent reduction of retinal microvascular vessel density in patients with moderate and severe COVID-19 disease. *BMJ Open Ophthalmol.* 2022 Jan 11;7(1):e000867. doi: [10.1136/bmjophth-2021-000867](https://doi.org/10.1136/bmjophth-2021-000867). PMID: [35039796](https://pubmed.ncbi.nlm.nih.gov/35039796/); PMCID: [PMC8753095](https://pubmed.ncbi.nlm.nih.gov/PMC8753095/).
72. Aydemir E, Aydemir GA, Atesoglu HI, Goker YS, Ozcelik KC, Kiziltoprak H. The Impact of Coronavirus Disease 2019 (COVID-19) on Retinal Microcirculation in Human Subjects. *Klin Monbl Augenheilkd.* 2021 Dec;238(12):1305-1311. English. doi: [10.1055/a-1579-0805](https://doi.org/10.1055/a-1579-0805). Epub 2021 Sep 29. PMID: [34587629](https://pubmed.ncbi.nlm.nih.gov/34587629/).
73. Sanjay S, Agrawal S, Jayadev C, Kawali A, Gowda PB, Shetty R, Mahendradas P. Posterior segment manifestations and imaging features post-COVID-19. *Med Hypothesis Discov Innov Ophthalmol.* 2021 Nov 17;10(3):95-106. doi: [10.51329/mehdiophthal1427](https://doi.org/10.51329/mehdiophthal1427). PMID: [37641707](https://pubmed.ncbi.nlm.nih.gov/37641707/); PMCID: [PMC10460223](https://pubmed.ncbi.nlm.nih.gov/PMC10460223/).
74. Hösel K, von der Burchard C, Schunk D, Franzenburg J, Bahmer T, Frank D, Dargvainiene J, Roeder JB. Okuläre Manifestationen bei COVID-19-Patienten [Ocular manifestations in patients with COVID-19]. *Ophthalmologie.* 2022 Aug;119(8):807-812. German. doi: [10.1007/s00347-022-01581-y](https://doi.org/10.1007/s00347-022-01581-y). Epub 2022 Jan 28. PMID: [35089415](https://pubmed.ncbi.nlm.nih.gov/35089415/); PMCID: [PMC8796747](https://pubmed.ncbi.nlm.nih.gov/PMC8796747/).
75. Hodroj MH, Bashshur ZF, Wahab C, Jarrah K, Taher A. Coronavirus Disease 2019 (COVID-19)-associated central retinal vein occlusion: a case report and literature review. *Archives of Hematology Case Reports and Reviews.* 2022 Mar 3;7(1):009-12. doi: [10.17352/ahcrr.000037](https://doi.org/10.17352/ahcrr.000037).
76. Jidigam VK, Singh R, Batoki JC, Milliner C, Sawant OB, Bonilha VL, Rao S. Histopathological assessments reveal retinal vascular changes, inflammation, and gliosis in patients with lethal COVID-19. *Graefes Arch Clin Exp Ophthalmol.* 2022 Apr;260(4):1275-1288. doi: [10.1007/s00417-021-05460-1](https://doi.org/10.1007/s00417-021-05460-1). Epub 2021 Oct 29. PMID: [34714382](https://pubmed.ncbi.nlm.nih.gov/34714382/); PMCID: [PMC8553591](https://pubmed.ncbi.nlm.nih.gov/PMC8553591/).
77. Eberhardt N, Noval MG, Kaur R, Amadori L, Gildea M, Sajja S, Das D, Cilhoro B, Stewart O, Fernandez DM, Shamailova R, Guillen AV, Jangra S, Schotsaert M, Newman JD, Faries P, Maldonado T, Rockman C, Rapkiewicz A, Stapleford KA, Narula N, Moore KJ, Giannarelli C. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. *Nat Cardiovasc Res.* 2023 Oct;2(10):899-916. doi: [10.1038/s44161-023-00336-5](https://doi.org/10.1038/s44161-023-00336-5). Epub 2023 Sep 28. PMID: [38076343](https://pubmed.ncbi.nlm.nih.gov/38076343/); PMCID: [PMC10702930](https://pubmed.ncbi.nlm.nih.gov/PMC10702930/).
78. Abbati G, Fazi C, Fortunato P, Trapani S. Central retinal artery occlusion in a young child affected by COVID-19: a first case report. *BMC Pediatr.* 2023 Sep 13;23(1):462. doi: [10.1186/s12887-023-04276-8](https://doi.org/10.1186/s12887-023-04276-8). PMID: [37704960](https://pubmed.ncbi.nlm.nih.gov/37704960/); PMCID: [PMC10500751](https://pubmed.ncbi.nlm.nih.gov/PMC10500751/).
79. Stawowski AR, Konopińska J, Stawowski SS, Adamczuk J, Groth M, Moniuszko-Malinowska A, Czupryna P. The Review of Ophthalmic Symptoms in COVID-19. *Clin Ophthalmol.* 2024 May 23;18:1417-1432. doi: [10.2147/OPHTH.S460224](https://doi.org/10.2147/OPHTH.S460224). PMID: [38803556](https://pubmed.ncbi.nlm.nih.gov/38803556/); PMCID: [PMC11129748](https://pubmed.ncbi.nlm.nih.gov/PMC11129748/).
80. Looi MK. Covid-19: Scientists sound alarm over new BA.2.86 "Pirola" variant. *BMJ.* 2023 Aug 24;382:1964. doi: [10.1136/bmj.p1964](https://doi.org/10.1136/bmj.p1964). PMID: [37620014](https://pubmed.ncbi.nlm.nih.gov/37620014/).
81. Ng HW, Scott DAR, Danesh-Meyer HV, Smith JR, McGhee CN, Niederer RL. Ocular manifestations of COVID-19. *Prog Retin Eye Res.* 2024 Sep;102:101285. doi: [10.1016/j.preteyeres.2024.101285](https://doi.org/10.1016/j.preteyeres.2024.101285). Epub 2024 Jun 24. PMID: [38925508](https://pubmed.ncbi.nlm.nih.gov/38925508/).
82. Eissa M, Abdelrazek NA, Saady M. Covid-19 and its relation to the human eye: transmission, infection, and ocular manifestations. *Graefes Arch Clin Exp Ophthalmol.* 2023 Jul;261(7):1771-1780. doi: [10.1007/s00417-022-05954-6](https://doi.org/10.1007/s00417-022-05954-6). Epub 2022 Dec 31. PMID: [36585987](https://pubmed.ncbi.nlm.nih.gov/36585987/); PMCID: [PMC9803899](https://pubmed.ncbi.nlm.nih.gov/PMC9803899/).



83. Patel NT, Martinek A, Shaikh R, Kahar P, Khanna D. COVID-19 and Its Ophthalmic Manifestations: A Literature Review. *Cureus*. 2024 Mar 5;16(3):e55571. doi: [10.7759/cureus.55571](https://doi.org/10.7759/cureus.55571). PMID: 38576676; PMCID: PMC10993080.
84. Parmar UPS, Surico PL, Singh RB, Musa M, Scarabosio A, Surico G, Maniaci A, Lavallo S, D'Esposito F, Longo A, Russo A, Gagliano C, Zeppieri M. Ocular Implications of COVID-19 Infection and Vaccine-Related Adverse Events. *J Pers Med*. 2024 Jul 23;14(8):780. doi: [10.3390/jpm14080780](https://doi.org/10.3390/jpm14080780). PMID: 39201972; PMCID: PMC11355216.
85. Salvetat ML, Zeppieri M. Management of COVID-19 in Ophthalmology. *Adv Exp Med Biol*. 2024;1457:401-429. doi: [10.1007/978-3-031-61939-7\\_23](https://doi.org/10.1007/978-3-031-61939-7_23). PMID: 39283440.
86. Micevych PS, Stewart JM. Retinal and choroidal vascular diseases associated with COVID-19. In *Retinal and Choroidal Vascular Diseases of the Eye* 2024 Jan 1 (pp. 605-614). Academic Press. doi: [10.1016/B978-0-443-15583-3.00046-9](https://doi.org/10.1016/B978-0-443-15583-3.00046-9).
87. Lam WY, Au SCL. Big data are needed for analysis of the association of retinal vascular occlusion and COVID-19. *Graefes Arch Clin Exp Ophthalmol*. 2023 Sep;261(9):2717-2718. doi: [10.1007/s00417-023-06043-y](https://doi.org/10.1007/s00417-023-06043-y). Epub 2023 Apr 3. PMID: 37009962; PMCID: PMC10068241.
88. Chung YR, Yeo S, Kim H. Big data are needed for analysis of the association of retinal vascular occlusion and COVID-19. *Graefes Arch Clin Exp Ophthalmol*. 2023 Sep;261(9):2719-2720. doi: [10.1007/s00417-023-06044-x](https://doi.org/10.1007/s00417-023-06044-x). Epub 2023 Mar 28. PMID: 36976355; PMCID: PMC10043514.